Table 2 Src kinase inhibitors in clinical trial phases
From: Recent advances in pharmacological diversification of Src family kinase inhibitors
Drug | Conditions | Phase of trial | Estimated study completion date |
|---|---|---|---|
Dasatinib | Triple negative breast neoplasms | Phase 2 | May 2021 |
JAB-3312 | Non-small-cell lung cancer| colorectal cancer| pancreatic ductal carcinoma| esophageal squamous cell carcinoma| head and neck squamous cell carcinoma| breast cancer| other solid tumors | Phase 1 | Aug 2021 |
Dasatinib| Ganitumab | Rhabdomyosarcoma| Rhabdomyosarcoma- alveolar| Rhabdomyosarcoma-embryonal | Phase 1|Phase 2 | 31 Oct 2021 |
Dasatinib Bevacizumab Paclitaxel | Advanced cancer | Phase 1 | Nov 2021 |
Dasatinib Osimertinib | EGFR gene mutation| non-small-cell lung cancer | Phase 1|Phase 2 | Nov 2021 |
SC-43 Oral Solution | Refractory solid tumor | Phase 1 | Nov 2021 |
Ruxolitinib | Head and neck squamous cell carcinoma | Phase 2 | 30 Jun 2022 |
Degarelix| Enzalutamide| Trametinib| Dasatinib | Prostate cancer | Phase 2 | 30 Sep 2022 |
Dasatinib | Leukemia | Phase 1 | 4 Oct 2022 |
Apatinib Mesylate Tablets Bevacizumab Injection | Gastrointestinal neoplasms | Phase 2 | 31 Dec 2022 |
Ponatinib and Cytarabine | Acute myeloid leukemia | Phase 1|Phase 2 | Nov 2023 |
TPX-0022 | Advanced solid tumor| metastatic solid tumors| MET gene alterations | Phase1 | Nov 2023 |
TPX-0046 | Non-small cell lung cancer| medullary thyroid cancer| RET gene mutation| metastatic solid tumor| advanced solid tumor | Phase 1|Phase 2 | Mar 2025 |